Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321

Watchlist Manager
Shenzhen Chipscreen Biosciences Co Ltd Logo
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Watchlist
Price: 21.02 CNY -8.49% Market Closed
Market Cap: 8.6B CNY
Have any thoughts about
Shenzhen Chipscreen Biosciences Co Ltd?
Write Note

Shenzhen Chipscreen Biosciences Co Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shenzhen Chipscreen Biosciences Co Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Shenzhen Chipscreen Biosciences Co Ltd
SSE:688321
Long-Term Investments
ÂĄ376.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Long-Term Investments
ÂĄ684.7m
CAGR 3-Years
189%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Long-Term Investments
ÂĄ571.9m
CAGR 3-Years
-14%
CAGR 5-Years
-11%
CAGR 10-Years
1%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Long-Term Investments
ÂĄ1.5B
CAGR 3-Years
-10%
CAGR 5-Years
53%
CAGR 10-Years
77%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Long-Term Investments
ÂĄ12.7B
CAGR 3-Years
120%
CAGR 5-Years
31%
CAGR 10-Years
68%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Long-Term Investments
ÂĄ1.6m
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shenzhen Chipscreen Biosciences Co Ltd
Glance View

Market Cap
8.6B CNY
Industry
Pharmaceuticals

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. The company is headquartered in Shenzhen, Guangdong and currently employs 909 full-time employees. The company went IPO on 2019-08-12. The firm focuses on the research and development of original innovative drugs in five therapeutic areas, including malignant tumors, metabolic diseases, autoimmune diseases, central nervous system diseases and anti-virus. The firm's main products include Chidamide, Siglitazone, Cioroni and CS12192. The firm mainly conducts its businesses in the domestic market.

Intrinsic Value
12.22 CNY
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Investments?
Long-Term Investments
376.9m CNY

Based on the financial report for Sep 30, 2024, Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Investments amounts to 376.9m CNY.

What is Shenzhen Chipscreen Biosciences Co Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 1Y
1%

Over the last year, the Long-Term Investments growth was 1%.

Back to Top